Vir Biotechnology is an immunology company that develops products to treat and prevent infectious diseases and other serious conditions.
Vir Biotechnology has raised $150.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in February 2026.
Vir Biotechnology's investors include ARCH Venture Partners, 8VC, Bill & Melinda Gates Foundation, SoftBank Vision Fund, Google Ventures.
Vir Biotechnology is headquartered in San Francisco, United States.
Vir Biotechnology is an immunology company that develops products to treat and prevent infectious diseases and other serious conditions.
Vir Biotechnology is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Vir Biotechnology — Funding & Investors." VCBacked, February 25, 2026, https://www.vcbacked.co/company/vir-biotechnology. Accessed August 14, 2026.
VCBacked. (2026). Vir Biotechnology — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/vir-biotechnology
{{cite web |title=Vir Biotechnology — Funding & Investors |url=https://www.vcbacked.co/company/vir-biotechnology |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated